ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1915

Pathogenetic Overlap Between Localised and Systemic Scleroderma: A Study of Nodular and Keloidal Morphea Occurring in Systemic Sclerosis

Emma C. Derrett-Smith1, Nataliya Gak2, Svetlana I. Nihtyanova3, Voon H. Ong3, Victoria Swale2, Cate Orteu2 and Christopher P. Denton4, 1Centre for Rheumatology and Connective Tissue Diseases,, UCL Division of Medicine, London, United Kingdom, 2Royal Free London NHS Foundation Trust, London, United Kingdom, 3Rheumatology, UCL Division of Medicine, London, United Kingdom, 4Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Fibroblasts, Gene Expression, histopathologic, morphea and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Localised scleroderma can occur in
overlap with systemic sclerosis (SSc); nodular and keloidal morphea are rare subtypes
but can be disfiguring and challenging to treat. Published literature suggests
that keloid scarring and SSc skin share TGFbeta regulated gene expression alterations
and that nodular and keloidal morphea represent a spectrum of keloid formation
in SSc.  This study aims to determine the pathological differences between these
conditions and addresses the hypothesis that bone marrow derived fibroblast
progenitors (fibrocytes) link them.

Methods: We examined a clinical database of 2200 patients
with SSc defined by ACR/EULAR classification criteria to identify patients with
a clinical or pathological diagnosis of localised scleroderma. The demographics,
clinical features and laboratory parameters of those with nodular or keloidal
morphea were examined in detail. We identified structural and biochemical
differences by examining paired skin biopsies from these lesions and standard
forearm biopsy site in SSc (n=6).  Skin biopsies from patients with both early
and established diffuse cutaneous SSc were used as controls.

Results: 49 patients (2.2%) had both localised scleroderma
and SSc. Data from this group were broadly comparable to the SSc cohort,
excepting a higher prevalence in females (female:male ratio 11:1). Three
subtypes of localised scleroderma were prevalent: plaque morphea (67%); linear
morphea (8.0%) and nodular or keloidal morphea (25%). Plaque and linear morphea
patients had predominantly  limited cutaneous SSc (88% and 75% respectively)
while the majority of nodular/keloidal morphea patients had diffuse cutaneous
SSc (92%, p<0.001). There were no clear serological associations. Keloid
nodules were localised on the upper chest rather than areas of high SSc skin
disease activity. Examination of histology in 5 of 12 patients with nodular/keloidal
morphea identified acute inflammatory infiltrates, mucin deposition and altered
distribution of collagen compared to SSc skin biopsies. Expression analysis of
TGFbeta regulated genes identified multiple significant differences in
expression within morphea lesions and at other sites in the same patients
(figure 1). A significant increase in CCl2 expression may be associated with
fibrocyte recruitment.

Conclusion: This is the largest analysis of localised scleroderma
in SSc. There are associations of subtypes of localised scleroderma with
subsets of SSc which are not related to serology. Paired examination of
histological samples and gene expression of nodular or keloidal SSc skin identifies
increased TGFbeta downstream activity compared with other biopsy sites
suggesting that this mediator may be a key driver of localised scleroderma in
SSc.

 


Disclosure: E. C. Derrett-Smith, None; N. Gak, None; S. I. Nihtyanova, None; V. H. Ong, None; V. Swale, None; C. Orteu, None; C. P. Denton, GlaxoSmithKline, 2,Actelion Pharmaceuticals US, 5,GlaxoSmithKline, 5,Serono, 5,Inventiva, 5,CSL Behring, 2,Bayer, 5.

To cite this abstract in AMA style:

Derrett-Smith EC, Gak N, Nihtyanova SI, Ong VH, Swale V, Orteu C, Denton CP. Pathogenetic Overlap Between Localised and Systemic Scleroderma: A Study of Nodular and Keloidal Morphea Occurring in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/pathogenetic-overlap-between-localised-and-systemic-scleroderma-a-study-of-nodular-and-keloidal-morphea-occurring-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pathogenetic-overlap-between-localised-and-systemic-scleroderma-a-study-of-nodular-and-keloidal-morphea-occurring-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology